

The 2nd International Multidisciplinary Anal Cancer Conference

9-10 November, 2023 at Catholic University of Sacred Heart - Policlinico Agostino Gemelli, Rome, Italy

Program

Thursday, 9 November

- 08:30-09:00** Arrival and registration
- 09:00-09:05** Welcome and introduction session
Karen-Lise Garm Spindler, Aarhus, Denmark and Maria Antonietta Gambacorta, Rome, Italy
- 09:05-09:25** Keynote lecture; Anal Cancer – the perspective
Vincenzo Valentini, Rome, Italy
- 09:25-09:40** Inequalities in anal cancer treatment – how can we contribute?
Eva Segelov, Bern, Switzerland
- 09:40-10:00** Panel discussion with patient representatives
Moderated by Pierfrancesco Franco, Novara, Italy and Eva Segelov, Bern, Switzerland
- 10:00-13:00** Session 1: Clinical Trials status, update, and perspectives for collaboration
Chairs: Marianne Guren, Oslo, Norway and David Sebag-Montefiore, Leeds, UK
- 10:00-10:15** Clinical trials for anal cancer - what have we learnt and what can we do better?
David Sebag-Montefiore, Leeds, UK
- 10:15-10:30** Evaluating immunotherapy in the curative treatment of anal cancer
Rob Glynne-Jones, London, UK
- 10:30-11:00** Coffee
- 11:00-11:15** Defining new standards of care for advanced disease
Sheela Rao, Sutton, UK

- 11:15-11:30 Future novel agents on the horizon for anal cancer**
Dirk Arnold, Hamburg, Germany
- 11:30-12:15 Oxford debate: this house believes that neo-adjuvant chemotherapy is a useful treatment strategy for patients with non-metastatic anal cancer**
Chair: David Sebag-Montefiore, Leeds, UK
- Pro - Veronique Vendrely, Bordeaux, France*
Con - Rob Glynn-Jones, London, UK
- 12:15-13:00 Proffered papers/trial updates**
Chairs: TBC
- 13:00-14:00 Lunch**
- 14:00-17:00 Session 2: Biology, Basic and translational science**
Chairs: Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark
- 14:00-14:15 IRCI anal cancer translational science group work**
Duncan Gilbert, London, UK
- 14:15-14:30 Hypoxia in SCC Anal cancer, results and perspectives**
Karen Wind, Aarhus, Denmark
- 14:30-14:45 PDX generations, and potential use for collaboration – DK**
Morten Busk, Aarhus, Denmark
- 14:45-15:00 Microbiome**
Antonio Gasbarrini, Rome, Italy
- 15:00-15:15 SCCA organoids**
TBC
- 15:15-15:30 Imaging biomarkers in anal cancer**
TBC
- 15:30-16:00 Coffee**
- 16:00-16:15 What is the biological difference between HPV positive and negative disease?**
Andrew McDonald, Leeds, UK
- 16:15-16:30 pHPV studies in SCC – update from pan-scam**
Karen-Lise Garm Spindler, Aarhus, Denmark
- 16:30- 17:00 Proffered papers flash talks**
Chairs: TBC


17:00-17:30 Discussion topics

Moderated by Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark

17:30-18:30 Poster session including drinks and snacks

Chairs: Anders Johnson, Lund, Sweden, Marianne Guren, Oslo, Norway, and Per Nilsson, Stockholm, Sweden

19:00- Conference dinner



Friday, 10 November

- 09:00-10:15** Session 3: Improved radiotherapy
Chairs: Pierfrancesco Franco, Novara, Italy and Maria Antonietta Gambacorta, Rome, Italy
- 09:00-09:15** Where are the limitations with current IMRT based therapy?
Pierfrancesco Franco, Novara, Italy
- 09:15-09:30** Optimal imaging assessment and new diagnostic tools
TBC
- 09:30-09:45** Risk adapted target definition
Martin Nilsson, Lund, Sweden
- 09:45-10:00** AtomCat for all? Update for utility?
Ane Appelt, Leeds, UK
- 10:00-10:15** Potential of Ethos therapy
Eva Serup-Hansen, Herlev, Denmark
- 10:15-10:30** Potential of the MR-linac in anal cancer
TBC
- 10:30-11:00** Coffee
- 11:00-12:00** Session 3: Improved radiotherapy (continued)
- 11:00-11:15** Role of brachytherapy in anal cancer
Bruno Fionda, Rome, Italy
- 11:15-11:30** Proton therapy in anal cancer
Camilla Kronborg, Aarhus, Denmark
- 11:30-11:45** Management of radiation proctitis
Carlo Ratto, Rome, Italy
- 11:45-12:45** Lunch
- 12:45-14:00** Proffered papers
Chair: Stefania Manfrida, Rome, Italy
- 14:00-15:00** IMACC Discussion
Facilitation of international collaboration, focus and research on anal cancer
Moderated by Dirk Arnold, Hamburg, Germany and David Sebag-Montefiore, Leeds, UK

This program may be subject to minor changes.